When Gilead Sciences Inc declined to project 2014 revenue for its high-profile new hepatitis C drug last week, its shares fell nearly 7 percent over the next two days. Wall Street analysts say investors were likely spooked by the omission, concerned it could signal that sales of the new drug, Sovaldi, might not approach sky-high forecasts. On Tuesday, Gilead President and Chief Operating Officer John Milligan again declined to predict sales of the medicine that won U.S. marketing approval in December.
Help employers find you! Check out all the jobs and post your resume.
